The Non-Invasive Prenatal Testing Market Size is valued at USD 4.63 billion in 2023 and is predicted to reach USD 12.20 billion by the year 2031 at a 13.02 % CAGR during the forecast period for 2024-2031.
Non-invasive prenatal testing, often known as non-invasive prenatal screening, is a method for determining the likelihood that a fetus will have genetic abnormalities. This type of screening is risk-free and remarkably successful for Down syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, and other genetic conditions. By week 10 of pregnancy, little DNA fragments are detected in pregnant women's blood, which is frequently examined. Reduced fertility, high blood pressure, increased risk of miscarriage, stillbirths, and maternal mortality are just a few health problems that might arise as a mother ages. Maternal age can also increase the likelihood of genetic disorders in babies due to incorrect chromosomal division.
The demand for non-invasive prenatal diagnostics is therefore anticipated to increase as maternal age and the prevalence of chromosomal disorders both rise. The market's organic revenue growth is driven by an increase in the majority of chromosomal abnormalities and increased product usage in new applications. Additionally, improvements in existing tests' chemistry, usefulness, and bioinformatics analysis are anticipated to fuel market expansion. The market for non-invasive prenatal testing is driven by older women's more significant chance of having infants with Down syndrome.
Furthermore, the rise in children with chromosomal problems and advancements in diagnostic imaging technology drives the demand for non-invasive prenatal testing. The market for non-invasive prenatal diagnostics is anticipated to benefit from expanding insurance coverage for typical and low-risk pregnancies. However, the high cost of testing and provisional diagnostic tools restricts the market's growth. Two more issues that could impede the expansion of the global non-invasive prenatal testing market are the decreased per capita healthcare spending and the inadequate test reimbursement policies.
The non-invasive prenatal testing market is segmented by gestation period, pregnancy risk, method, technology, product, application, and end-user. Based on gestation period, the market is segmented into 0-12 weeks, 13-24 weeks, 25-36 weeks. The market is segmented by pregnancy risk into high & average risk, low risk. The market is segmented by method into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests. The market is segmented by technology into NGS, array technology, and others. The market is segmented by product into consumables & reagents, instruments. The market is segmented by application into trisomy, microdeletion syndrome, and other applications. The market is segmented by end-use into hospitals & clinics, diagnostic laboratories.
The cell-free DNA in maternal plasma tests category dominated the market. Various genetic tests are increasingly used in prenatal care to forecast the likelihood of genetic abnormalities. With the advent of whole-genome sequencing, technological developments have broadened the scope of testing and made it possible to identify many more chromosomal abnormalities, including microdeletions and sex-specific ones. However, the use of ultrasound detection as a complement to the NIPT test based on cell-free DNA results in a lower market share. However, more recent technological developments and 3D-4D imaging have enhanced the test's real-time monitoring, safety, and efficacy, which is further likely to fuel the segment's expansion.
The trisomy category dominated the market in 2021 because of increased chromosomal abnormalities. The prevalence of genetic illnesses is high in India. According to much research, trisomy 21 (down syndrome), which has a high incidence rate of 1 in 800 births and results in the birth of 32,000 children with down syndrome every year, is discovered in 1 in 166 newborns nationwide. Whole genome sequencing tests are now available, and they can identify a wide range of additional chromosomal abnormalities, including microdeletions and sex-specific ones.
The North American non-invasive prenatal testing market is expected to register the highest market share in revenue shortly. This can be attributable to several factors, including the high preterm birth rate, the developed healthcare system, and the rising maternal mortality rate. The prevalence of chromosomal abnormalities is rising, as is public awareness of the advantages of non-invasive prenatal testing. These factors are driving the market's expansion. The demand for non-invasive prenatal testing is increasing significantly due to the top firms' increased focus on diversifying their product lines, boosting the market's growth. In addition, the development of new, technologically sophisticated tests has a significant impact on the market expansion in this region. In addition, Asia Pacific is projected to grow rapidly in the global non-invasive prenatal testing market because of the expanding healthcare systems in developing nations like China and India, among others. Rising public healthcare spending and increased knowledge of non-invasive prenatal testing will be projected to boost market expansion. Additionally, non-invasive prenatal testing developments and technology improvements are anticipated to drive the market's growth during the projection period.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 4.63 Bn |
|
Revenue Forecast In 2031 |
USD 12.20 Bn |
|
Growth Rate CAGR |
CAGR of 13.02% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Gestation Period, By Pregnancy Risk, By Method, By Technology, By Product, By Application, By End-User, and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Genesis Genetics (CooperSurgical, Inc.), Natera, Inc., Eurofins LifeCodexx GmbH, Illumina, Inc. (Verinata Health, Inc.), Centogene N.V., MedGenome Labs Ltd., Myriad Women’s Health, Inc. (Counsyl, Inc.), F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics), Qiagen, Laboratory Corp. of America Holdings, Progenity, Inc., Quest Diagnostics, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-Invasive Prenatal Testing Market Snapshot
Chapter 4. Global Non-Invasive Prenatal Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Gestation Period Estimates & Trend Analysis
5.1. by Gestation Period & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Gestation Period:
5.2.1. 0-12 Weeks
5.2.2. 13-24 Weeks
5.2.3. 25-36 Weeks
Chapter 6. Market Segmentation 2: by Pregnancy Risk Estimates & Trend Analysis
6.1. by Pregnancy Risk & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Pregnancy Risk:
6.2.1. High & Average Risk
6.2.2. Low Risk
Chapter 7. Market Segmentation 3: by Method Estimates & Trend Analysis
7.1. by Method & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Method:
7.2.1. Ultrasound Detection
7.2.2. Biochemical Screening Tests
7.2.3. Cell-Free DNA in Maternal Plasma Tests
Chapter 8. Market Segmentation 4: by Technology Estimates & Trend Analysis
8.1. by Technology & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technology:
8.2.1. NGS
8.2.2. Array Technology
8.2.3. PCR
8.2.4. Others
Chapter 9. Market Segmentation 5: by Product Estimates & Trend Analysis
9.1. by Product & Market Share, 2019 & 2031
9.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product:
9.2.1. Consumables & Reagents
9.2.2. Instruments
Chapter 10. Market Segmentation 6: by Application Estimates & Trend Analysis
10.1. by Application & Market Share, 2019 & 2031
10.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
10.2.1. Trisomy
10.2.2. Microdeletion Syndrome
10.2.3. Other Applications
Chapter 11. Market Segmentation 7: by End-Use Estimates & Trend Analysis
11.1. by End-Use & Market Share, 2019 & 2031
11.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-Use:
11.2.1. Hospitals & Clinics
11.2.2. Diagnostic Laboratories
Chapter 12. Non-Invasive Prenatal Testing Market Segmentation 3: Regional Estimates & Trend Analysis
12.1. North America
12.1.1. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.1.2. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.1.3. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.1.4. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.1.5. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.1.6. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.1.7. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.1.8. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.2. Europe
12.2.1. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.2.2. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.2.3. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.2.4. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.2.5. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.2.6. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.2.7. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.2.8. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.3. Asia Pacific
12.3.1. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.3.2. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.3.3. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.3.4. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.3.5. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.3.6. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.3.7. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.3.8. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.4. Latin America
12.4.1. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.4.2. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.4.3. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.4.4. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.4.5. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.4.6. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.4.7. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.4.8. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.5. Middle East & Africa
12.5.1. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.5.2. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.5.3. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.5.4. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.5.5. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.5.6. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.5.7. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.5.8. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Genesis Genetics (CooperSurgical, Inc.)
13.2.2. Natera, Inc.
13.2.3. Eurofins LifeCodexx GmbH
13.2.4. Illumina, Inc. (Verinata Health, Inc.)
13.2.5. Centogene N.V.
13.2.6. MedGenome Labs Ltd.
13.2.7. Myriad Women’s Health, Inc. (Counsyl, Inc.)
13.2.8. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
13.2.9. Qiagen
13.2.10. Laboratory Corp. of America Holdings
13.2.11. Progenity, Inc.
13.2.12. Quest Diagnostics, Inc.
13.2.13. Other Prominent Players
Non-Invasive Prenatal Testing Market- By Gestation Period
Non-Invasive Prenatal Testing Market- By Pregnancy Risk
Non-Invasive Prenatal Testing Market- By Method
Non-Invasive Prenatal Testing Market- By Technology
Non-Invasive Prenatal Testing Market- By Product
Non-Invasive Prenatal Testing Market- By Application
Non-Invasive Prenatal Testing Market- By End-use
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
